Company Analysis
Sign in

Precision BioSciences, Inc. (DTIL)

Nasdaq: DTIL · Biological Products, (No Diagnostic Substances) · Durham, NC · filing with the SEC since 2006
Full chart Alerts Compare
Grade4.7
◀ Past 4.8● Present 4.6▶ Future 4.7
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

48 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Precision BioSciences, Inc.’s names, not what it holds today.

Patents granted
48
48 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 3 in 2024 and 5 in 2023
Applications published
138
20 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology17
Pharmaceuticals4
Medical technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Precision Biosciences, Inc. its own name
US, as the owner printed on each patent
48 granted
124 published
Precision BioSciences, Inc. its own name
named as the applicant on its applications, in US
0 granted
14 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 21, 202512,448,613Genetically-modified T cells comprising a modified intron in the T cell receptor alpha geneBiotechnologyPrecision Biosciences, Inc.
Sep 9, 202512,410,418Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genomeBiotechnologyPrecision Biosciences, Inc.
Jul 8, 202512,351,839Rationally-designed single-chain meganucleases with non-palindromic recognition sequencesBiotechnologyPrecision Biosciences, Inc.
Jun 11, 202412,006,522Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin geneBiotechnologyPrecision Biosciences, Inc.
May 28, 202411,993,793Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin geneBiotechnologyPrecision Biosciences, Inc.
Jan 9, 202411,866,747Engineered meganucleases that target human mitochondrial genomesPharmaceuticalsPrecision Biosciences, Inc.
Dec 26, 202311,851,680Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)BiotechnologyPrecision Biosciences, Inc.
Oct 17, 202311,788,077Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genomeBiotechnologyPrecision Biosciences, Inc.
Oct 17, 202311,786,554Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region geneMedical technologyPrecision Biosciences, Inc.
Sep 12, 202311,753,630Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin geneBiotechnologyPrecision Biosciences, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 18, 20252025/0382641POLYPEPTIDE LINKERS FOR USE IN ENGINEERED MEGANUCLEASESBiotechnologyPrecision Biosciences, Inc.
Nov 13, 20252025/0346877ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOMEPharmaceuticalsPrecision Biosciences, Inc.
Oct 30, 20252025/0333468OPTIMIZED ENGINEERED NUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENEMedical technologyPrecision Biosciences, Inc.
Oct 9, 20252025/0313816GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED TRANSFERRIN GENEBiotechnologyPrecision Biosciences, Inc.
Oct 2, 20252025/0304949GENETIC MODIFICATION OF THE HYDROXYACID OXIDASE 1 GENE FOR TREATMENT OF PRIMARY HYPEROXALURIABiotechnologyPrecision Biosciences, Inc.
Jul 17, 20252025/0228973GENE EDITING METHODS FOR TREATING ALPHA-1 ANTITRYPSIN (AAT) DEFICIENCYPharmaceuticalsPrecision BioSciences, Inc.
May 29, 20252025/0171757OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOMEBiotechnologyPrecision Biosciences, Inc.
May 15, 20252025/0154486ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE HEPATITIS B VIRUS GENOMEPharmaceuticalsPrecision Biosciences, Inc.
May 15, 20252025/0154485RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCESBiotechnologyPrecision Biosciences, Inc.
May 15, 20252025/0154481ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE PCSK9 GENEBiotechnologyPrecision Biosciences, Inc.
What it applied for, 2024 to 2025: Biotechnology 26 · Pharmaceuticals 13 · Medical technology 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton DTIL · research, not advice